---
title: "Sonoma Pharmaceuticals, Inc. (SNOA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/SNOA.US.md"
symbol: "SNOA.US"
name: "Sonoma Pharmaceuticals, Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-21T13:48:52.037Z"
locales:
  - [en](https://longbridge.com/en/quote/SNOA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SNOA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SNOA.US.md)
---

# Sonoma Pharmaceuticals, Inc. (SNOA.US)

## Company Overview

Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [onomapharma.com](https://onomapharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:18.000Z

**Overall: C (0.47)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 108 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 26.83% |  |
| Net Profit YoY | 10.09% |  |
| P/B Ratio | 0.54 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1863323.68 |  |
| Revenue | 17722000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -81.19% | E |
| Profit Margin | -19.02% | D |
| Gross Margin | 37.94% | B |
| Revenue YoY | 26.83% | A |
| Net Profit YoY | 10.09% | C |
| Total Assets YoY | -0.33% | D |
| Net Assets YoY | -29.53% | E |
| Cash Flow Margin | 104.12% | C |
| OCF YoY | 26.83% | A |
| Turnover | 1.30 | A |
| Gearing Ratio | 74.81% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Sonoma Pharmaceuticals, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "26.83%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "10.09%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.54",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "1863323.68",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "17722000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-81.19%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-19.02%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "37.94%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "26.83%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "10.09%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "-0.33%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-29.53%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "104.12%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "26.83%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "1.30",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "74.81%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.55 | 89/190 | - | - | - |
| PB | 0.54 | 22/190 | 1.64 | 1.43 | 1.11 |
| PS (TTM) | 0.11 | 6/190 | 0.43 | 0.35 | 0.25 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-08T05:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.08 |
| Highest Target | 12.00 |
| Lowest Target | 12.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/SNOA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/SNOA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/SNOA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/SNOA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**